All In Biotech

Drug Trial Radar · NCT04442737

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

A Phase 4, Randomized, Active-Controlled, Open-label Study to Evaluate the Safety and Tolerability of Switching to Once-Daily Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Regimen in Virologically-suppressed Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Experiencing Rapid Weight Gain With an INI + TAF/FTC ARV Regimen

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Jul 1, 2020

Primary completion

Aug 7, 2023

Study completion Aug 30, 2023

Sponsor

Lead sponsor
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the percent change in body weight when switching to darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) (Immediate Switch Arm) compared to continuing the current integrase (INI) + tenofovir alafenamide/emtricitabine (TAF/FTC) antiretroviral (ARV) regimen (Delayed Switch Arm) in virologically-suppressed human immunodeficiency virus (HIV)-1 infected participants who have experienced rapid and significant body weight gain.

Conditions

  • HIV-1

Interventions

  • D/C/F/TAF FDCDrug

    A FDC tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg will be administered once daily.

  • TAF/FTC FDCDrug

    TAF/FTC ARV regimen will be administered once daily.

  • INI Based RegimenDrug

    The integrase (INI) inhibitors (for example, bictegravir, dolutegravir, elvitegravir/cobicistat, and raltegravir) will be administered in combination with TAF/FTC, as appropriate. Regimen may consist of a single tablet regimen or a combination of two separate pills.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body Weight at Week 24Time frame: Baseline and Week 24
  2. Percent Change From Baseline in Body Weight at Week 24: Body Mass Index (BMI) >=30 Kilograms Per Square Meter (kg/m^2) SubgroupTime frame: Baseline and Week 24
  3. Percent Change From Baseline in Body Weight at Week 24: Female and Male SubgroupTime frame: Baseline and Week 24
  4. Percent Change From Baseline in Body Weight at Week 24: Black/African American and Black/African American- Female SubgroupsTime frame: Baseline and Week 24
  5. Percent Change From Baseline in Body Weight at Week 24: Non-Black/African American SubgroupTime frame: Baseline and Week 24

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • The Office of Franco Felizarta, MD

    Bakersfield, California

  • AIDS Health Foundation-Westside HCC

    Beverly Hills, California

  • Long Beach Education & Research Consultants

    Long Beach, California

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • University of Miami

    Miami, Florida

  • Triple O Research Institute

    West Palm Beach, Florida

  • Atlanta ID Group

    Atlanta, Georgia

  • Medical College of Georgia

    Augusta, Georgia

  • The Corporation of Mercer University

    Macon, Georgia

  • Chatham County Health Department

    Savannah, Georgia

  • The Ruth M. Rothstein CORE Center

    Chicago, Illinois

  • Care South Clinic

    Baton Rouge, Louisiana

  • Kaiser Permanente

    Rockville, Maryland

  • Community Research Initiative

    Boston, Massachusetts

  • Be Well Medical Center, PC

    Berkley, Michigan

  • Henry Ford Health System

    Detroit, Michigan

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Washington University School Of Medicine

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • Saint Michaels Medical Center - Infectious Disease

    Newark, New Jersey

  • AIDS Healthcare Foundation-Research Center

    New York, New York

  • Mount Sinai Hospital-New York

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Philadelphia Fight

    Philadelphia, Pennsylvania

  • Palmetto Health - USC

    Columbia, South Carolina

  • AIDS Arms Incorporated Trinity Health and Wellness Center

    Dallas, Texas

  • North Texas Infectious Diseases Consultants

    Dallas, Texas

  • Texas Centers for Infectious Disease Associates

    Fort Worth, Texas

  • Therapeutic Concepts - Donald R Watkins Foundation

    Houston, Texas

  • DCOL Center for Clinical Research

    Longview, Texas

  • Infectious Disease Associates of Central Virginia

    Lynchburg, Virginia

  • Vivent Health

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.